Research Area
|
Description
|
Infection |
Biological Activity
|
Description
|
Azalomycin-B (Elaiophylin) shows antiprotozoal activity against Plasmodium falciparum K1a and Trypanosoma brucei brucei GUTat 3.1 strains with IC50 of 0.36 μM and 0.45 μM, respectively. |
Targets
|
|
|
|
|
|
|
IC50 |
|
|
|
|
|
|
In Vitro
|
Azalomycin-B possesses an antibacterial activity against Gram-positive bacteria. The minimum inhibitory concentration (MIC) of Azalomycin-B against Staphylococcus aureus (SG 511, 285 and 503) is 1.52 μM. The MIC of Azalomycin-B against Streptococcus pyogenes is 0.76 μM and 1.52 μM for strains 306A, and 77A, respectively. The MIC of Azalomycin-B against S. faecium A is 3.05 μM. [1] In vitro, Azalomycin-B shows an antibiotic activity as a rumen fermentation efficiency enhancer and also inhibits lactic acid production in the rumen fluid with IC5O of 2.14 μM. [2] Azalomycin-B inhibits P-type ATPases such as the P-type, K+-dependent ATPase from Escherichia coli, without affecting F-type and V-type ATPases at all. [3] Azalomycin-B shows the potent cytotoxic effect on L929 mouse fibroblast cells, K562 human leukemia cells and HeLa cell cultures with IC50 of 0.29 μM, 0.19 μM and 0.29 μg/mL, respectively. [4] Moreover, Azalomycin-B also produces the cytotoxicity in MRC-5 cells with IC50 of 0.85 μM. [5] |
In Vivo
|
|
Clinical Trials
|
|
Features
|
Azalomycin-B is a macrolide antibiotic showing the antiprotozoal activity against Plasmodium falciparum K1a and Trypanosoma brucei brucei GUTat 3.1 strains. |
Combination Therapy
|
Description
|
Azalomycin-B (μg/mL) markedly enhances Rapamycin (μg/mL)'s antifungal activity against Candida albicans ATCC 11651 as high as 219%. [6] |
Protocol
|
Cell Assay
[4]
|
Cell Lines |
L92, K562 and HeLa cells |
Concentrations |
0-10 μM |
Incubation Time |
72 hours |
Methods |
The adherent mouse fibroblast cell line L-929 is cultured in Eagle's MEM with 0.35 mg/mL sodium bicarbonate, 100 units/mL penicillin/100 μg/mL streptomycin, 10 mM HEPES, and 10% heat-inactivated FBS at 37 °C in culture flasks. The adherent cells are harvested at the logarithmic growth phase after trypsination using 0.05% trypsin in phosphate-buffered saline (PBS) containing 0.02% EDTA. The nonadherent human leukemia cell line K-562, is cultured in RPMI 1640 medium, supplemented with 100 units/mL penicillin/100 μg/mL streptomycin and 10% FBS in culture flasks. L-929 and K-562 cells are inoculated in 0.1 mL culture medium, containing NaHCO3 without HEPES, per well of the 96-well microplates. The plates are previously prepared with dilutions of the Azalomycin-B in 0.1 mL medium. The microplates are kept for 72 hour at 37 °C in a humidified atmosphere containing 5% CO2. The adherent human cell line HeLa is cultured in MEM Eagle with 100 units/mL penicillin/100 μg/mL streptomycin, 10% FBS, and 2 mM l-glutamine in vented culture flasks. The adherent cells are harvested during the logarithmic growth phase after trypsination with 0.4% trypsin in PBS containing 0.02% EDTA. These cells are seeded with in 0.1 mL culture medium per well of the 96-well microplates. HeLa cells are preincubated 48 hours without Azalomycin-B. The dilutions of Azalomycin-B are carried out on the monolayer of HeLa cells after preincubation time. After incubation, the monolayer of the adherent L-929 and HeLa cells are fixed by glutaraldehyde and stained with a 0.05% solution of methylene blue for 15 minutes. After washing the stain is eluted by 0.2 mL of 0.33 N HCl in the wells. The optical densities are measured at 630 nm in a Dynatech MR 7000 microplate reader. After incubation, the K-562 cells are analyzed using an electronic cell analyzer system CASY 1 and software CASYSTAT for determination of IC50 values. The IC50 values are determined by integrated software CASYSTAT. |
References |
[1] Hammann P, et al. J Antibiot (Tokyo). 1990, 43(11), 1431-1440.
|
[2] Liu CM, et al. J Antibiot (Tokyo). 1993, 46(2), 350-352.
|
[3] Dröse S, et al. Biochemistry. 1993, 32(15), 3902-3906.
|
[4] Ritzau M, et al. J Nat Prod. 1998, 61(11), 1337-1339.
|
[5] Otoguro K, et al. J Antibiot (Tokyo). 2010, 63(5), 275-277.
|
[6] Fang A, et al. J Antibiot (Tokyo). 2000, 53(2), 158-162.
|
|